Pacific Edge Annual Report 2020

Pacific Edge’s Annual Report for the year ended 31 March 2020 is now available. We invite you to read the document, along with our Annual Review Letter, at www.pacificedgedx.com/investors/shareholder-reports/.
 
We continue to make good progress in our journey to commercialise our Cxbladder tests in the global market. 
 
In FY20, all our key performance metrics increased year on year. Highlights for the period included the publication of three additional peer reviewed papers in support of Cxbladder; inclusion in the National Comprehensive Cancer Network (NCCN) guidelines in the US; increased adoption and commercial use by New Zealand’s public healthcare providers and growing recognition and adoption by urologists in the US and New Zealand.
 
The past few months have been an extraordinary time for countries and businesses around the globe, as together we have faced the challenges of Covid-19. We have seen an acceleration of trends that have been progressing slowly for many years, such as the move to telehealth and new ways of doing things are quickly becoming the norm. 
 
For Pacific Edge, the global pandemic circumstances have highlighted the benefits of our Cxbladder tests, providing assurance to patients, simplifying the diagnostic process and allowing for easy, non-invasive in-home sample collection, all while providing high quality results for clinicians. 
 
The benefits of this additional utility was reflected in the recent agreement with leading US healthcare provider, Kaiser Permanente, which has approved the commercial use of Cxbladder by their urologists for patients being evaluated for bladder cancer. This is a significant milestone achievement for our company. 
 
In all our markets, our commercial focus remains on the large scale, blue chip healthcare organisations, such as Kaiser Permanente, which can benefit from adopting Cxbladder and which will also deliver greater scale and volumes over the long term.
 
We remain committed to realising the significant opportunity that exists for Cxbladder, and we are progressing in a number of areas which will help us achieve our goals of growing our global reach, building and strengthening our customer base and increasing sales and adoption, all of which will drive greater cash revenue.

Regards, Pacific Edge Limited